Key Highlights
- Geoff Nosrati, Ph.D., appointed as Chief Business Officer, bringing over 20 years of biotech industry experience.
- Martin Oft, M.D., assumes the role of Chief Scientific Officer, leveraging his expertise in cytokine therapeutics.
- Greg Yedinak promoted to Chief Technical Officer, with a focus on advancing Synthekine’s novel immunotherapies into clinical development.
Source: Business Wire
Notable Quote
- “Geoff is an accomplished biotechnology executive… His experience in portfolio strategy and transactions will be an asset to Synthekine… Martin’s deep insights into cytokine biology… were instrumental to shaping the development of STK-012… Greg’s broad expertise… has allowed us to advance both STK-012 and STK-009 + SYNCAR-001 into clinical development.” – Debanjan Ray, CEO at Synthekine
SoHC's Take
The strategic restructuring of Synthekine’s executive leadership heralds a promising phase for the company, emphasizing a deep commitment to advancing its innovative cytokine therapeutics portfolio. With the appointment of Geoff Nosrati and the promotions of Martin Oft and Greg Yedinak, Synthekine is well-positioned to leverage its unique insights into cytokine biology to develop next-generation immunotherapies. These leadership changes underscore the company’s dedication to pushing the boundaries of science to improve treatment options for cancer and inflammatory diseases, marking a significant step forward in their mission to provide improved efficacy and safety in cytokine-based treatments.
